GlassScriptPhysician profile
Vanessa Y Wang
NPI 1285165464
$9,623.85
in general payments reported to CMS, 2019-2025
33 companies · $3,196 in 2025
The $3,196 reported for 2025 was more than what 98% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $494 · 2022: $1,543 · 2023: $1,873 · 2024: $2,517 · 2025: $3,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,586.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,612.26 | 2021-2025 | |
| Lilly USA, LLC | $1,099.84 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Ardelyx, INC. | $861.33 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $770.78 | 2022-2025 | Verquvo, Gardasil 9, Capvaxive |
| Otsuka America Pharmaceutical, INC. | $515.25 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $491.49 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $479.40 | 2021-2025 | Evenity, Prolia, Prolia |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $415.59 | 2023-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $354.18 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $332.82 | 2024-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $297.87 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $256.98 | 2022-2024 | Xarelto |
| Novo Nordisk INC | $249.88 | 2021-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $235.80 | 2023-2025 | |
| Esperion Therapeutics, INC. | $225.75 | 2024-2025 | Nexletol |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $217.84 | 2021-2025 | Trintellix |
| Lundbeck LLC | $189.45 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $149.31 | 2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Radius Health, INC. | $143.01 | 2021-2024 | Tymlos |
| Biohaven Pharmaceutical Holding Company LTD. | $140.62 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $137.09 | 2024-2025 | Zoryve |
| Axsome Therapeutics, INC. | $60.00 | 2025 | Auvelity |
| Ibsa Pharma INC. | $59.33 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.62 | 2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $54.17 | 2024 | Voquezna |
| Astellas Pharma US INC | $40.05 | 2021 | |
| Aimmune Therapeutics, INC. | $40.00 | 2025 | Zenpep |
| Vanda Pharmaceuticals INC. | $32.78 | 2024 | Fanapt |
| Amarin Pharma, INC. | $23.06 | 2022 | |
| Nestle Healthcare Nutrition INC. | $23.03 | 2023 | |
| Oyster Point Pharma, INC. | $20.07 | 2023 | Tyrvaya |
| Sanofi-Aventis U.S. LLC | $18.75 | 2022 | |
| Alkermes, INC. | $18.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.